Mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, in combination with bevacizumab in patients with platinum-sensitive ovarian cancer: results from a phase 1 study

International Journal of Gynecological Cancer 2026

View at publisher

Authors: Changyu Wang, Hongying Yang, Jundong Li, J. Tang, Ke Wang, Yuehua Wang, An Lin, L. Chen, Juan Li, Lingshuang Ren, Wenzhao Hang, L. Chen

+2 more

Xiaoqing Zhang, D. Ma

DOI: 10.1016/j.ijgc.2026.104572

Cited by: 1

Fields of Study & Subjects

HER2/EGFR in Cancer Research PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment